PreveCeutical Medical Inc. PRVCF Archives - Page 2 of 6

ThursdayAug 30, 2018 12:47 pm

Update Highlights PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Efforts to Establish Nature-Based Health and Wellness Products

Preventative health care market expected to see 15 percent CAGR in build toward $196.9 billion in revenues by 2024 PreveCeutical Medical conducting five R&D programs that aim to boost preventative health for cancers, head injuries Recent investor update highlights company’s cannabis product development efforts, including sleep aid product agreement with Asterion Cannabis Inc. PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) recently published an investor update detailing its corporate activities (http://ibn.fm/37FYr), particularly as they relate to its efforts to improve public health through a novel delivery method for cannabis-related products. The report notes PreveCeutical’s successes, underscored by its completion of…

WednesdayAug 22, 2018 1:30 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Issues Shareholder Update Highlighting Recent Milestones

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning issued a shareholder update on its ongoing corporate initiatives. Among the highlights discussed in the news release, the company entered into a natural health product licensing agreement with Asterion Cannabis Inc., launched its medicinal cannabis division, completed a $6.5 million financing and expanded its Australian operations. As noted, these milestones serve as evidence of PreveCeutical’s continued execution of its strategy to become a global preventative health care company. To view the full press release, visit http://ibn.fm/DSBae About PreveCeutical Medical Inc. PreveCeutical is a health sciences company…

WednesdayAug 22, 2018 12:18 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Acquires Worldwide License for Herbal Sleep Aids

Millions worldwide affected by sleep disorders Sleep disorder market set to exceed $50 billion by 2020 New marketing initiative kicks off with engagement of IR firm Updated Crystal Equity Research report now available Counting sheep may soon be a thing of the past, for PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has been awarded a worldwide license to manufacture, distribute and market three Health Canada-approved sleep aids (http://ibn.fm/rO8AV). This milestone could not have come at a better time. Sleeping disorders affect around 40 percent of adults in Canada (approximately 15 million), according to a study conducted at the Université…

WednesdayAug 15, 2018 11:25 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Inks Licensing Agreement with Asterion Cannabis; Engages Monster Media to Provide IR Services

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed an agreement with Asterion Cannabis Inc. to acquire a worldwide license to use, manufacture, distribute and sell three Health Canada approved natural health products. Per the terms of the licensing agreement, Asterion has granted PreveCeutical a non-exclusive license to use Asterion's intellectual property to make or have made, use, distribute, sell, offer to sell and promote the products in exchange for a royalty fee payable to Asterion equaling 20% of the gross sales. The licensing agreement’s initial term is five years and…

MondayAug 13, 2018 12:07 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is Named for its Attention to Preventative Health Care

Private placement of $4.9 million in June 2018 Five R&D programs currently underway Preventative health care market set to reach $200 billion by 2025 PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it…

WednesdayAug 08, 2018 10:55 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Unveils Medicinal Cannabis Division’s First Product Development Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the first product development program of the company’s newly created medicinal cannabis division, which will focus on the development of cannabinoids as a preventative treatment for anxiety disorders using PreveCeutical’s proprietary Sol-gel delivery platform. Per the update, the goal of the medical cannabis division’s program is to “create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.” According to data from the Mayo Clinic, common approaches to treating anxiety, such as the prescription…

FridayAug 03, 2018 11:50 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies

PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them. The biotech company based in British…

TuesdayJul 31, 2018 1:32 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Posts Update on Scorpion Venom-Derived Peptide Program

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today issued an update regarding the second phase of its three phase, scorpion venom-derived peptide research and development program. The program consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom. The goal of the program is to empower PreveCeutical to produce Nature Identical™ peptide therapeutics to treat, regulate and prevent cancer progression. The company’s initial focus will target glioblastoma, a highly-aggressive form of brain cancer. PreveCeutical has started phase 2 of the program, comprised of re-designing the peptides to enhance their biostability while upholding their potency…

FridayJul 27, 2018 12:44 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Establishes Business Unit for $55 Billion Medical Marijuana Market

Medical indications for marijuana multiply Medical marijuana (MMJ) market moves mainstream New cannabis business unit to focus on MMJ market Now that some 44 nations around the globe have passed laws allowing marijuana for medical use, the market is set for rapid expansion in the coming years. Industry analysts Grand View Research estimate that the global medical marijuana market will reach a value of $55.8 billion by 2025, as the range of therapies for cannabis multiplies (http://ibn.fm/hHyKV). Much of this expected demand will be driven by treatments for chronic pain, but applications are also likely to be developed for a number of other…

WednesdayJul 25, 2018 12:44 pm

PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Breakthrough Sol-gel Drug Delivery Platform Featured in Proactive Investors Interview

PreveCeutical was recently featured in an interview by Proactive Investors The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids Sol-gel technology is paving the way for direct nose-to-brain drug delivery Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://ibn.fm/ryrqu). The company earlier provided a written press release updating the Sol-gel program (http://ibn.fm/Bww8y). Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF